Lucid Diagnostics Inc.
LUCD
$1.26
-$0.03-2.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.89% | 79.00% | 179.27% | 379.19% | 370.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.89% | 79.00% | 179.27% | 379.19% | 370.50% |
| Cost of Revenue | 11.07% | 18.73% | 4.45% | 3.77% | 37.43% |
| Gross Profit | 14.88% | 22.47% | 52.08% | 52.00% | 16.06% |
| SG&A Expenses | 17.09% | 2.45% | -6.19% | -12.92% | -21.44% |
| Depreciation & Amortization | -76.70% | -70.34% | -46.42% | -24.85% | -9.80% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.10% | -1.20% | -7.82% | -13.70% | -18.65% |
| Operating Income | -5.99% | 5.22% | 13.21% | 19.34% | 22.88% |
| Income Before Tax | -31.46% | 13.55% | 21.05% | 18.01% | 21.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.46% | 13.55% | 21.05% | 18.01% | 21.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.46% | 13.55% | 21.05% | 18.01% | 21.81% |
| EBIT | -5.99% | 5.22% | 13.21% | 19.34% | 22.88% |
| EBITDA | -9.85% | 2.60% | 12.04% | 19.35% | 23.67% |
| EPS Basic | 5.87% | 15.03% | 19.57% | 16.16% | 20.60% |
| Normalized Basic EPS | 26.00% | 29.80% | 27.77% | 31.64% | 34.16% |
| EPS Diluted | 5.87% | 15.03% | 19.57% | 16.16% | 20.60% |
| Normalized Diluted EPS | 26.00% | 29.80% | 27.77% | 31.64% | 34.16% |
| Average Basic Shares Outstanding | 31.99% | 20.95% | 14.73% | 13.30% | 13.63% |
| Average Diluted Shares Outstanding | 31.99% | 20.95% | 14.73% | 13.30% | 13.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |